# A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.

> **NCT00390858** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 40 (actual)

## Conditions studied

- Transfusional Iron Overload
- β-thalassemia Major
- Pediatric Rare Anemia

## Interventions

- **DRUG:** Deferasirox

## Key facts

- **NCT ID:** NCT00390858
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00390858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00390858, "A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00390858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*